Analysts Set Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Price Target at $19.73

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) has received an average rating of “Moderate Buy” from the twelve brokerages that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $20.20.

A number of brokerages have issued reports on BCYC. Citizens Jmp upped their target price on Bicycle Therapeutics from $10.00 to $12.00 and gave the company a “market outperform” rating in a research report on Friday, October 31st. Citigroup restated an “outperform” rating on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Monday, December 22nd. Royal Bank Of Canada reiterated a “sector perform” rating and set a $11.00 price objective (down from $27.00) on shares of Bicycle Therapeutics in a research note on Friday, October 31st. Finally, Truist Financial started coverage on shares of Bicycle Therapeutics in a research report on Monday, November 24th. They issued a “hold” rating and a $10.00 target price for the company.

Insider Activity

In other news, CFO Alethia Young sold 4,334 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $6.49, for a total value of $28,127.66. Following the completion of the sale, the chief financial officer directly owned 87,081 shares in the company, valued at approximately $565,155.69. The trade was a 4.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin Lee sold 10,989 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $6.46, for a total value of $70,988.94. Following the sale, the chief executive officer directly owned 618,996 shares in the company, valued at approximately $3,998,714.16. This represents a 1.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 38,029 shares of company stock valued at $251,966. 22.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Bicycle Therapeutics

A number of hedge funds have recently added to or reduced their stakes in BCYC. Assetmark Inc. raised its holdings in shares of Bicycle Therapeutics by 74.9% during the third quarter. Assetmark Inc. now owns 3,625 shares of the company’s stock worth $28,000 after purchasing an additional 1,552 shares during the period. Ausdal Financial Partners Inc. acquired a new position in shares of Bicycle Therapeutics in the 2nd quarter valued at about $70,000. Sei Investments Co. bought a new stake in shares of Bicycle Therapeutics during the 2nd quarter valued at about $74,000. Virtus Investment Advisers LLC raised its stake in Bicycle Therapeutics by 32.6% during the second quarter. Virtus Investment Advisers LLC now owns 10,821 shares of the company’s stock worth $75,000 after acquiring an additional 2,659 shares during the period. Finally, Ameriprise Financial Inc. bought a new position in Bicycle Therapeutics in the second quarter worth about $86,000. Institutional investors and hedge funds own 86.15% of the company’s stock.

Bicycle Therapeutics Price Performance

Shares of Bicycle Therapeutics stock opened at $7.22 on Tuesday. Bicycle Therapeutics has a 1-year low of $6.03 and a 1-year high of $13.66. The company has a market capitalization of $500.85 million, a PE ratio of -1.99 and a beta of 1.52. The business has a 50-day moving average of $6.88 and a 200-day moving average of $7.37.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings results on Thursday, October 30th. The company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($1.09) by $0.24. Bicycle Therapeutics had a negative return on equity of 36.05% and a negative net margin of 884.51%.The business had revenue of $11.73 million for the quarter, compared to analysts’ expectations of $8.25 million. On average, equities analysts expect that Bicycle Therapeutics will post -3.06 earnings per share for the current fiscal year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.